JMF
VRTX icon

Johnson Midwest Financial’s Vertex Pharmaceuticals VRTX Stock Holding History

Johnson Midwest Financial’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$17K Hold
49
– – 0.04% 155
2023
Q2 		$17.2K Hold
49
– – 0.02% 163
2023
Q1 		$15.4K Hold
49
– – 0.02% 167
2022
Q4 		$14K Buy
+49
New +$14.9K 0.05% 169

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Johnson Midwest Financial's VRTX Position: Q3 2023 in Review

Johnson Midwest Financial held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2023 at 49 shares worth $17K. The position accounts for 0.04% of the portfolio, ranked #155.

Johnson Midwest Financial first reported a position in VRTX in Q4 2022 and has held it in 4 quarters since. The position peaked at $17.2K in Q2 2023. 1,277 funds tracked by Wall St. Rank hold VRTX as of Q3 2023.

  • Johnson Midwest Financial held 49 shares of Vertex Pharmaceuticals worth $17K as of Q3 2023.
  • Johnson Midwest Financial left its Vertex Pharmaceuticals share count unchanged in Q3 2023.
  • Vertex Pharmaceuticals made up 0.04% of Johnson Midwest Financial's portfolio in Q3 2023, its #155 holding.
  • Johnson Midwest Financial first reported a position in Vertex Pharmaceuticals in Q4 2022 and has held it in 4 quarters since.
  • Johnson Midwest Financial's Vertex Pharmaceuticals position peaked at $17.2K in Q2 2023.
  • 1,277 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2023.

Based on Johnson Midwest Financial's 13F filing for Q3 2023, filed 7 Nov 2023.